SUMMARY We describe eight patients treated for angina with prenylamine who developed lifethreatening ventricular arrhythmias after QT interval prolongation. When prenylamine administration was stopped QT interval shortened to within normal values, while the ventricular arrhythmias were controlled by a temporary ventricular pacemaker and disappeared after several days. We stress the importance of surveillance of the QT interval and ventricular arrhythmias in patients receiving long-term treatment with prenylamine.
Since its introduction as an antianginal agent, prenylamine has been shown to have a wide margin of therapeutic safety.' Indeed very few lifethreatening complications of prenylamine treatment have been reported.2-5 Thus the association of ventricular arrhythmias with prenylamine is of some interest, especially in view of the fact that it can be anticipated and thus avoided.
We report on the mode of treatment of eight patients with prolonged QT intervals and serious symptomatic ventricular tachyarrhythmias caused by prenylamine.
Patients and results
The eight patients constituting this group were admitted to the Department of Cardiology at the Lady Davis Carmel Hospital because of several Received for publication 26 February 1980 episodes of syncope in the few weeks preceding admission.
They had coronary artery disease with mild anginal syndrome and were on a regimen of prenylamine 180 to 240 mg/day for at least two months before being admitted to hospital. Clinical details and additional drugs are summarised in the Table. On arrival all patients had electrocardiograms showing prolonged QT interval, ventricular premature beats, and short runs of ventricular tachycardia with torsade de pointes pattern ( Fig. 1-4 ).
In the first four patients treatment with lignocaine was initiated immediately; this failed, however, to control the arrhythmia. Moreover, two patients (cases 1 and 3) developed transient Mobitz second and third degree atrioventricular block on being given a 100 mg bolus of intravenous ligno- values in all eight patients with concomitant cessation of the ventricular arrhythmias two to four days after prenylamine was discontinued (Fig. 6) .
On admission none of these patients had clinical, electrocardiographic, or enzymatic signs of myocardial ischaemia or infarction. Serum potassium, magnesium, and calcium (Table) QT prolongation may be a result of ischaemic heart disease,11 hypokalaemia, hypocalcaemia,' hypomagnesaemia,1 several antiarrhythmic drugs,' Prenvlamine-znduced ventricular treatment with phenothiazines'5 18 and tricyclic compounds,'6 liquid protein diets,'7 and is a feature of the Jervell-Lange-Nielson'8 19 and the RomanoWard syndromes.20 21 QT prolongation encourages re-entry processes and ventricular arrhythmias including torsade de pointes. Torsade de pointes may also arise during slow heart rhythm as an escape mechanism in sinus node dysfunction and atrioventricular block.2223 It has also been reported in a neonate with myocarditis24 and as a rare complication of ventricular pacing. 25 In the eight cases described above we wish to draw attention to the prolongation of the QT interval induced by prenylamine, which was followed by torsade de pointes. The effects were reversible and controlled by ventricular pacing. All eight patients were examined echocardiographically and phonocardiographically and none was found to have prolapse of the mitral valve or any cardiomyopathy detectable by these tests. In all cases the prolonged QT intervals returned to normal values within several days after withdrawal of prenylamine, with the concomitant disappearance of the ventricular arrhythmias. Neither syncope nor palpitation has recurred in any of our patients on follow-up, and none has shown conduction disorders or arrhythmias.
The occurrence of atrioventricular block after an intravenous bolus of lignocaine is of some interest. The drug normally asserts minimal effects on the cardiac conducting system, and heart block induced by lignocaine is a rare complication.26 Thus the induction of atrioventricular block in two patients of four to whom lignocaine was given is a source of some misgiving. Though unconfirmed, we cannot discount the possibility that at least in some cases lignocaine may be inadvisable in torsade de pointes.
The confident diagnosis of torsade de pointes requires the simultaneous recording of three leads; not every run of ventricular extrasystoles which change shape can be given this label. In view of the urgency of the situation we recorded only two leads ( Fig. 1 and 2 
